Related Experiment Videos
Hyperkalemia associated with cyclosporine (CsA) use in bone marrow transplantation
D R Fleming1, R Ouseph, J Herrington
1Department of Internal Medicine, University of Kentucky Medical Center, Louisville, USA.
Insights
Cyclosporine can cause hyperkalemia in leukemia patients undergoing bone marrow transplants, even with normal kidney function. This study explores management strategies for this common cyclosporine side effect in transplant recipients.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Allogeneic bone marrow transplantation is a critical treatment for leukemia.
- Cyclosporine (CsA) is a key immunosuppressant used post-transplant.
- Electrolyte imbalances can complicate post-transplant recovery.
Observation:
- Two adult leukemia patients developed hyperkalemia despite adequate kidney function during CsA therapy.
- Cyclosporine was identified as the sole pharmaceutical cause of the electrolyte abnormality.
- The hyperkalemia appeared linked to an aldosterone-resistant state.
Findings:
- Cyclosporine-induced hyperkalemia is a recognized but underreported issue in bone marrow transplant patients.
- The study suggests potential mechanisms for CsA-associated hyperkalemia.
- Proposed management strategies for this condition in transplant recipients are discussed.
Implications:
- Highlights the need for vigilant electrolyte monitoring in patients receiving CsA post-transplant.
- Informs clinical practice regarding the management of hyperkalemia in bone marrow transplant recipients.
- Contributes to understanding drug-induced electrolyte disturbances in immunocompromised patients.
Abstract:
Two adult leukemia patients underwent allogeneic bone marrow transplantation and received cyclosporine (CsA) as part of their immunosuppressive therapy. Despite adequate kidney function, both patients developed hyperkalemia. Cyclosporine was the only pharmaceutical agent to which this electrolyte abnormality could be attributed. Although the mechanism of the hyperkalemia is unclear, it seems to be related to an aldosterone-resistant state. Cyclosporine-induced hyperkalemia is a relatively common occurrence; however, there is only a single 'case report' addressing this phenomenon in bone marrow transplantation patients. We propose both mechanisms and methods of managing CsA-associated hyperkalemia in allogeneic transplantation patients.